Astec LifeSciences cash flow

Latest FY26

Cash from operations: −₹80.7cr−₹8.4 cr in FY25
Capital spending: ₹5.5cr−74.6% on FY25
Free cash flow: −₹86.2cr−₹30.2 cr in FY25
Cash from financing: ₹94.5cr+298.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	44.9	43.7	36.3	33.7
	—	34.5	36.7	25.2	20.7
	—	−0.5	−0.8	−0.2	−4.0
	—	0.1	0.0	0.3	0.3
	—	−2.2	3.2	−0.1	−1.5
	—	0.0	18.2	0.1	−0.1
	—	0.1	0.0	0.1	0.5
	—	1.9	0.0	0.0	0.0
	—	20.6	15.9	98.9	−109
	—	−92.1	18.9	−13.5	122
	—	−0.3	1.7	0.2	3.9
	—	0.0	0.0	0.0	0.0
	—	−13.6	−1.3	15.5	1.5
	—	0.2	0.2	−0.0	−8.2
	—	0.0	0.0	−0.0	0.1
	—	4.3	−7.8	−88.8	−14.3
	—	0.6	0.5	0.1	1.0
	—	−0.3	−1.8	0.7	0.3
	—	−0.4	0.4	−2.3	−3.2
	—	2.1	−0.2	1.6	1.0
	—	0.9	0.0	0.0	0.0
Cash from operating activities
	−79.7	−81.0	−141	−61.7	34.9
	—	0.9	128	73.9	44.6
	—	−80.1	−13.4	12.2	79.5
	—	0.6	−5.0	2.0	4.9
	—	−80.7	−8.4	10.2	74.7
Cash from investing activities
	—	5.5	21.8	135	117
	—	0.7	6.0	0.4	0.8
	—	0.6	0.8	0.2	4.1
	—	−0.1	−0.2	−0.3	−0.1
	—	−4.3	−15.2	−135	−113
Cash from financing activities
	—	236	0.0	0.1	0.0
	—	0.0	0.0	0.0	0.1
	—	0.0	171	199	103
	—	109	109	48.0	42.7
	—	32.6	38.6	23.2	20.1
	—	0.0	0.0	2.9	2.9
	—	94.5	23.7	125	37.8
	—	9.5	0.1	−0.0	−0.1
	—	9.5	0.1	−0.0	−0.1
	—	—	—	0.5	0.5
Reference items
	−7.3	−4.5	−66.2	−5.9	76.3
	−1.7%	−1.0%	−17.4%	−1.3%	12.1%
	−86.2	−86.2	−30.2	−125	−42.6
	—	−224	−8.1	4.2	—
	−₹38.71	−₹38.71	−₹13.56	−₹56.22	−₹19.12
	—	1.00×	0.06×	−0.22×	2.92×
	—	0.6	−5.0	2.0	4.9
	—	32.6	38.6	23.2	20.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ASTEC₹581.05

Astec LifeSciences Limited

· Chemicals

₹ CrorePeersPUNJABCHEM MOL IPL INSECTICID DHARMAJ BHARATRAS ADVANCE HERANBAMcap ₹1,295 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	33.7	36.3	43.7	44.9	—
+ Finance Costs	20.7	25.2	36.7	34.5	—
+ Interest Income	-4.0	-0.2	-0.8	-0.5	—
+ Share-based Payments	0.3	0.3	0.0	0.1	—
+ Unrealised FX (Gain) / Loss	-1.5	-0.1	3.2	-2.2	—
+ Other Non-cash Items	-0.1	0.1	18.2	0.0	—
+ Other — Cash Effects are Investing / Financing	0.5	0.1	0.0	0.1	—
+ Other Reconciling Items	0.0	0.0	0.0	1.9	—
Changes in Working Capital
+ Inventories	-108.8	98.9	15.9	20.6	—
+ Trade Receivables — Current	121.6	-13.5	18.9	-92.1	—
+ Other Financial Assets — Current	3.9	0.2	1.7	-0.3	—
+ Other Financial Assets — Non-current	0.0	0.0	0.0	0.0	—
+ Other Current Assets	1.5	15.5	-1.3	-13.6	—
+ Other Non-current Assets	-8.2	-0.0	0.2	0.2	—
+ Other Bank Balances	0.1	-0.0	0.0	0.0	—
+ Trade Payables — Current	-14.3	-88.8	-7.8	4.3	—
+ Other Financial Liabilities — Current	1.0	0.1	0.5	0.6	—
+ Other Financial Liabilities — Non-current	0.3	0.7	-1.8	-0.3	—
+ Other Current Liabilities	-3.2	-2.3	0.4	-0.4	—
+ Provisions — Current	1.0	1.6	-0.2	2.1	—
+ Provisions — Non-current	0.0	0.0	0.0	0.9	—
Cash from Operating Activities
Profit Before Tax (per I/S)	34.9	-61.7	-141.0	-81.0	-79.7
+ Total Adjustments (incl. Working Capital)	44.6	73.9	127.6	0.9	—
Cash from Operations (pre-tax)	79.5	12.2	-13.4	-80.1	—
+ Income Taxes Paid	4.9	2.0	-5.0	0.6	—
Cash from Operating Activities	74.7	10.2	-8.4	-80.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	117.3	135.5	21.8	5.5	—
+ Disp of Fixed Assets	0.8	0.4	6.0	0.7	—
+ Interest Received — Investing	4.1	0.2	0.8	0.6	—
+ Other Inflows / (Outflows) — Investing	-0.1	-0.3	-0.2	-0.1	—
Cash from Investing Activities	-112.5	-135.2	-15.2	-4.3	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.1	0.0	236.2	—
+ Proceeds from Exercise of Stock Options	0.1	0.0	0.0	0.0	—
+ Proceeds from Borrowings	103.3	199.0	171.0	0.0	—
+ Repayment of Borrowings	42.7	48.0	108.7	109.1	—
+ Interest Paid	20.1	23.2	38.6	32.6	—
+ Dividends Paid	2.9	2.9	0.0	0.0	—
Cash from Financing Activities	37.8	125.0	23.7	94.5	—
Net Changes in Cash (pre-FX)	-0.1	-0.0	0.1	9.5	—
Net Changes in Cash	-0.1	-0.0	0.1	9.5	—
Closing Cash	0.5	0.5	—	—	—
Reference Items
EBITDA	76.3	-5.9	-66.2	-4.5	-7.3
EBITDA Margin %	12.14	-1.29	-17.36	-1.01	-1.67
Free Cash Flow (CFO − Capex)	-42.6	-125.3	-30.2	-86.2	-86.2
Free Cash Flow to Equity	—	4.2	-8.1	-224.4	—
Free Cash Flow per Basic Share	-19.12	-56.22	-13.56	-38.71	-38.71
Cash Flow to Net Income	2.92	-0.22	0.06	1.00	—
Cash Paid for Taxes	4.9	2.0	-5.0	0.6	—
Cash Paid for Interest	20.1	23.2	38.6	32.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.